Dernières nouvelles pour Blueprint Medicines (NASDAQ:BPMC) Stock

BLUEPRINT MEDICINES CORP

Blueprint Medicines

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines Corp

On Monday, Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) said bezuclastinib showed meaningful clinical benefit for patients with non-<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">advanced systemic mastocytosis</a>.
The company said that its experimental drug reduced the symptoms of a chronic immune disorder called non-advanced systemic mastocytosis.
The latest study demonstrated meaningful and highly statistically significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46273670/why-is-cogent-biosciences-stock-trading-higher-on-monday-2" rel="noreferrer noopener">objective measures of mast cell burden</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46273670/why-is-cogent-biosciences-stock-trading-higher-on-monday-2" rel="noreferrer noopener">Why Is Cogent Biosciences Stock Trading Higher On Monday?</a>
The SUMMIT trial achieved its primary endpoint with a statistically significant difference in the mean change in total symptom score (TSS) at 24 weeks.
The bezuclastinib arm had a mean reduction of 24.3 points in TSS at 24 weeks, versus the placebo arm, which had a mean reduction of 15.4 points, resulting in a placebo-adjusted TSS improvement of 8.91 points.
Based on these data, Cogent is on track to submit its first new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in NonAdvSM by the end of 2025.
Further underscoring the drug&#8217;s potential, JP Morgan views the asset as very strategically attractive. &#8220;We believe the SUMMIT Part 2 bezuclastinib results were near a best-case outcome on the emerging clinical profile in NonAdvSM, particularly on the safety side (removing a key overhang on the program),&#8221; wrote analyst Anupam Rama in an investor note on Monday.
Consequently, JP Morgan maintains its overweight rating on Cogent with a<a target="_blank" href="https://www.benzinga.com/quote/COGT/analyst-ratings" rel="noreferrer noopener"> price forecast of $25</a>. In fact, JPMorgan believes Cogent&#8217;s bezuclastinib for systemic mastocytosis (SM) has strong potential to become a blockbuster drug and could set a new standard for future treatments.
From a market perspective, Cogent estimates the U.S. market worth over $2 billion for non-advanced SM and $300 million for advanced SM.
To provide context, Blueprint previously suggested the overall SM market could reach around $4 billion in peak sales, with its own drug Ayvakit projected to generate about $2 billion by 2030. Overall, the SM market is considered large and full of opportunity.
The analyst says the strategic attractiveness of the systemic mastocytosis market was recently validated by Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) acquisition of Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout" rel="noreferrer noopener">for over $9 billion</a>.
Beyond SM, JP Morgan also sees bezuclastinib&#8217;s potential in gastrointestinal stromal tumors (GIST) as underappreciated. The analyst adds, &#8220;We have been asked if a potential strategic interest in the asset would require positive data in GIST&#8230;and we do not believe so (SM is attractive on its own and GIST would be another lever of upside).
Looking ahead, Cogent remains on track to provide topline results from both PEAK, a Phase 3 trial of bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors, and APEX, a registration-directed trial of bezuclastinib in advanced systemic mastocytosis patients, during the second half of 2025.
Price Action: At the last check on Tuesday, COGT stock was up 6% at $9.911.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46300943/does-higher-dose-of-wegovy-result-in-more-weight-loss" target="_blank" rel="noreferrer noopener">Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Analyst Color

Biotech

News

Health Care

Analyst Ratings

Movers

General

BPMC

COGT

Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst

Wells Fargo analyst Derek Archila downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Overweight to Equal-Weight and lowers the price target from $143 to $129.

Downgrades

Price Target

Wells Fargo Downgrades Blueprint Medicines to Equal-Weight, Lowers Price Target to $129

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>UBS raised Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) price target from $160 to $207. UBS analyst William Appicelli maintained a Buy rating. Vistra shares closed at $177.20 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/VST/analyst-ratings">view this stoc</a>k.</li>
<li>Stephens &amp; Co. cut the price target for FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from $300 to $280. Stephens &amp; Co. analyst Daniel Imbro maintained an Overweight rating. FedEx shares closed at $226.74 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">view this stock</a>.</li>
<li>Wells Fargo cut Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) price target from $143 to $129. Wells Fargo analyst Derek Archila downgraded the stock from Overweight to Equal-Weight. Blueprint Medicines shares closed at $128.25 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">view this stock</a>.</li>
<li>Citigroup slashed the price target for McCormick &amp; Company, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) from $80 to $77. Citigroup analyst Thomas Palmer maintained a Neutral rating. McCormick shares closed at $73.90 on Monday. <a href="https://www.benzinga.com/quote/MKC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised the price target for NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) from $170 to $200. Barclays analyst Tom O&#8217;Malley maintained an Overweight rating. Nvidia shares closed at $144.69 on Monday. See how other <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">analysts view this stock</a>.</li>
<li>JP Morgan increased Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) price target from $245 to $305. JP Morgan analyst Bennett Moore maintained an Overweight rating. Carpenter Technology shares settled at $248.72 on Monday. <a href="https://www.benzinga.com/quote/CRS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS raised Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) price target from $33 to $42. UBS analyst Ashwani Verma upgraded the stock from Neutral to Buy. Alkermes shares closed at $29.42 on Monday. <a href="https://www.benzinga.com/quote/ALKS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital increased Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) price target from $80 to $100. Loop Capital analyst Alan Gould upgraded the stock from Hold to Buy. Roku shares closed at $82.17 on Monday.  <a href="https://www.benzinga.com/quote/ROKU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark boosted the price target for Belden Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) from $120 to $130. Benchmark analyst David Williams maintained a Buy rating. Belden shares settled at $109.56 on Monday. <a href="https://www.benzinga.com/quote/BDC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham increased Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) price target from $12 to $15. Needham analyst John Todaro maintained a Buy rating. Riot Platforms shares closed at $10.17 on Monday. <a href="https://www.benzinga.com/quote/RIOT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NVDA stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/NVDA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17095847/image-266-1024x574.png" alt="" class="wp-image-952367" style="width:611px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17095847/image-266-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17095847/image-266-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17095847/image-266-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17095847/image-266.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45968628/wall-streets-most-accurate-analysts-weigh-in-on-3-financial-stocks-with-over-15-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Financial Stocks With Over 15% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

ALKS

NVDA

RIOT

ROKU

Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday

Blueprint Medicines Reveals Data Reinforcing Sustained Clinical Efficacy And Well-Tolerated Safety Profile of Long-Term AYVAKIT/AYVAKYT Treatment At 2025 EHA And EAACI Congresses

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>Applied Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares escalated 102.93% following the announcement of a long-term <a href="https://www.benzinga.com//node/45817409" target="_blank" rel="noreferrer noopener">infrastructure agreement with</a> AI hyperscaler CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>).</li>
<li>Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) stock jumped 60.66%. The company revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class <a href="https://www.benzinga.com//node/45724030" target="_blank" rel="noreferrer noopener">oral STAT6 degrader medicine</a>. Morgan Stanley and B. Riley Securities upgraded the stock to Overweight and Buy, respectively, and the company <a href="https://www.benzinga.com/quote/kymr/analyst-ratings" target="_blank" rel="noreferrer noopener">received several price forecast bumps</a>.</li>
<li>First Majestic Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) stock increased 34.04% last week, when Silver rocketed past $35.60 an ounce Thursday, a level last seen in 2012. Gold bull Peter Schiff <a href="https://www.benzinga.com//node/45792880" target="_blank" rel="noreferrer noopener">says it's just warming up</a>.</li>
<li>AIFU Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFU#NASDAQ">AIFU</a>) shares rose 31.78%.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) shares increased 31.34% after the company announced the launch of <a href="https://www.benzinga.com//node/45814396" target="_blank" rel="noreferrer noopener">Boltz-2 in partnership with MIT</a>.</li>
<li>Cleveland-Cliffs Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) stock grew 30.36% after U.S. President Donald Trump announced <a href="https://www.benzinga.com//node/45724684" target="_blank" rel="noreferrer noopener">plans to double steel tariffs</a>.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) shares upped 26.44%. The company and NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) <a href="https://www.benzinga.com//node/45730717" target="_blank" rel="noreferrer noopener">therapy for pancreatic cancer</a>.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) stock rose 26.15% after the company announced that Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) <a href="https://www.benzinga.com//node/45719179" target="_blank" rel="noreferrer noopener">would acquire them for $9.5 billion</a>.</li>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) stock escalated 23.78% last week.</li>
<li>Riot Platforms, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) stock rose 22.06%. The company mined 514 bitcoin in May, up 11% month over month and <a href="https://www.benzinga.com//node/45752589" target="_blank" rel="noreferrer noopener">139% year over year</a>.</li>
</ol>
Photo by T. Schneider via Shutterstock

Equities

Mid Cap

AIFU

APLD

CRWV

KYMR

NVCR

RXRX

SEZL

ZLAB

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?

<h3 class="wp-block-heading">New On The Block</h3>
Byron Allen's Allen Media Group has hired Moelis &amp; Company to explore a sale of its TV stations across 21 markets. The company spent over $1 billion acquiring Big Four network affiliates (ABC, NBC, CBS, FOX) over the past six years. 
It is now looking to cash out and reduce debt. Deadline <a href="https://deadline.com/2025/06/allen-media-group-hires-investment-bank-to-sell-tv-stations-1236420381/">reported</a> that the TV stations have received multiple offers. 
Also for sale: 
<ul class="wp-block-list">
<li>Jefferies is shopping around PatientPoint, a health marketing and ad agency, according <a href="https://www.axios.com/pro/health-tech-deals/2025/06/04/patientpoint-jefferies-sale">to</a> Axios. L Catterton, Littlejohn &amp; Co. and Transformation Capital are on the sell side. </li>
<li>Just three years ago, private equity firm One Equity Partners <a href="https://www.oneequity.com/news/one-equity-partners-completes-investment-in-infucare-rx-a-leading-home-infusion-therapy-provider/">completed</a> a strategic investment in infusion provider InfuCare. Today? It&#8217;s looking to get rid of it. According to Axios, JPMorgan is <a href="https://www.axios.com/pro/health-tech-deals/2025/06/03/infucare-one-equity-jpmorgan-sale">looking</a> for a buyer. </li>
<li>Swiss biotech MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) received a <a href="https://www.benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report">bid exceeding $3 billion</a> from Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>). MoonLake turned down the initial offer, but talks are reportedly revived. The potential purchase signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cancer drug Keytruda</a> faces patent expiration as early as 2028.</li>
</ul>
<h3 class="wp-block-heading">Updates From The Block</h3>
<ul class="wp-block-list">
<li>Post Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) is forking over $880 million—including assumed debt—to buy 8th Avenue Food &amp; Provisions. That means brands like Ronzoni pasta will go back into Post&#8217;s pantry. <a href="https://www.wsj.com/articles/post-holdings-to-buy-ronzoni-pasta-owner-8th-avenue-food-cf8f454c?mod=deals_news_article_pos2">Per</a> The Wall Street Journal, the private-label brands originally got spun off into 8th Avenue in 2018 with help from private equity firm THL. Post plans to wipe out 8th Avenue's net debt and pick up the tab for all equity interests, including $111 million in finance leases. All in, the transaction is expected to cook up $15 million in annual synergies by the end of fiscal 2026. If Post closes by July 1, it expects 2026 to be more profitable (on an adjusted basis) than initially expected.</li>
</ul>
<ul class="wp-block-list">
<li>Rosebank Industries (LON: ROSE) is once again in talks to buy Electrical Components International (ECI), a wire harnesses manufacturer, for about $1.9 billion, Reuters reported. Rosebank was in talks to buy ECI in February but dropped the plans in March.</li>
</ul>
<ul class="wp-block-list">
<li>Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU. The acquisition will also include elenestinib, a next-generation medicine for SM, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential for immunology diseases. Sanofi will pay&nbsp;$129&nbsp;per share in cash, representing an equity value <a href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout">of roughly&nbsp;$9.1 billion</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Suzano S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>) is acquiring a 51% stake in a new $3.4 billion tissue products joint venture with Kimberly-Clark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NASDAQ">KMB</a>), <a href="https://www.benzinga.com/m-a/25/06/45797473/tissue-titans-unite-suzano-kimberly-clark-form-3-4-billion-global-jv">paying $1.734 billion in cash</a>. Kimberly-Clark will retain a 49% stake. The Netherlands-based venture will produce and distribute toilet paper and facial tissues in 70 countries, with 22 factories across 14 countries, employing about 9,000 people. The facilities have an annual capacity of 1 million tonnes and generated $3.3 billion in net sales in 2024.</li>
</ul>
<h3 class="wp-block-heading">Off The Block</h3>
<ul class="wp-block-list">
<li>Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45740112/robinhood-completes-200-million-bitstamp-deal-gains-access-to-500k-crypto-users-and-95-million-revenue-stream">completed its $200 million acquisition</a> of Bitstamp, a crypto exchange that had raised around $40 million from firms like Pantera Capital and Ripple.</li>
</ul>
<ul class="wp-block-list">
<li>Cactus Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) <a href="https://www.benzinga.com/m-a/25/06/45724879/cactus-takes-majority-stake-in-baker-hughes-spc-for-global-reach">formed a joint venture</a> with Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), taking a 65% stake and operational control of Baker Hughes&#8217; Surface Pressure Control (SPC) business. Baker Hughes will retain a 35% stake. The new venture, separate from Cactus' current pressure control unit, will focus on international wellhead and production tree systems.</li>
</ul>
<ul class="wp-block-list">
<li>Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is <a href="https://www.benzinga.com/pressreleases/25/06/b45719054/guardian-pharmacy-services-expands-pacific-northwest-footprint-with-acquisition-of-washington-base" target="_blank" rel="noreferrer noopener">entering the Pacific Northwest market</a> via acquisition. Mercury Pharmacy Services, a provider of long-term care pharmacy solutions, agreed to a price, but <a href="https://www.benzinga.com/m-a/25/06/45723960/guardian-pharmacy-strengthens-us-footprint-with-new-seattle-area-acquisition">the amount remains undisclosed</a>.</li>
</ul>
<h3 class="wp-block-heading">Bankruptcy Block</h3>
<ul class="wp-block-list">
<li>AI startup Builder.ai has filed for Chapter 7 bankruptcy in Delaware after creditors seized most of its cash, citing overstated 2024 sales projections—by a staggering 300%. Once valued at $1.5 billion, Builder.ai is now the biggest AI collapse since the ChatGPT-driven investment boom began. According <a href="https://www.bloomberg.com/news/articles/2025-06-05/builder-ai-files-for-bankruptcy-after-creditors-seize-accounts?sref=TBDibEcD">to</a> Bloomberg, the fallout was fueled by revelations that Builder.ai allegedly faked business with Indian social media firm VerSe Innovation to inflate revenues. VerSe co-founder Umang Bedi denies any wrongdoing, calling the claims "baseless and false."</li>
</ul>
<ul class="wp-block-list">
<li>Hooters closed some 30 corporate-owned restaurants and explained that it has <a href="https://www.businesswire.com/news/home/20250331979797/en/Hooters-of-America-Takes-Strategic-Action-to-Continue-its-Iconic-Legacy-Under-Pure-Franchise-Business-Model" target="_blank" rel="noreferrer noopener">no plans </a>to shut down any other locations. The Atlanta, Georgia-based restaurant chain went <a href="https://www.benzinga.com/personal-finance/25/04/44647084/hooters-files-for-bankruptcy-says-brand-isnt-going-anywhere">bankrupt earlier this year</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Alex Jones may see his personal assets — including guns, cars, and homes — sold by the end of the year, according to the Houston Chronicle, <a href="https://www.houstonchronicle.com/news/houston-texas/texas/article/alex-jones-personal-assets-sales-bankruptcy-20361565.php">citing</a> a bankruptcy trustee. The potential sale would mark the nearing end of his two-and-a-half-year bankruptcy process. Jones, who created the far-right conspiracy theory website Infowars, filed for bankruptcy in 2022 after being ordered to pay nearly $1.5 billion to families of Sandy Hook shooting victims for defamation.</li>
</ul>
<h3 class="wp-block-heading">Notes From The Block</h3>
A studio's IP portfolio and game development pipeline are critical for video game investors. A major acquirer in the sector is GDEV Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>). The Cyprus-based company has made three M&amp;A deals and spent $100 million on studio acquisitions since 2022. 
This week, Andrey Fadeev drafted <a href="https://www.benzinga.com/m-a/25/06/45722621/gdevs-founder-ceo-evaluates-m-a-deals-using-these-5-metrics">a listicle of key metrics</a> GDEV uses for M&amp;A evaluation.
<ol class="wp-block-list">
<li>LTV/CAC Ratio – Measures how efficiently a studio converts user acquisition spend into revenue. A ratio above 1.0 indicates profitable user growth.</li>
<li>Retention Rates (D1, D7, D30) – Track user engagement over time. High retention signals strong gameplay and monetization potential. Benchmarks vary by genre.</li>
<li>ARPU/ARPPU – Indicate monetization efficiency. ARPU includes all users; ARPPU focuses on paying users. Higher ARPU justifies higher CAC.</li>
<li>DAU/MAU Ratio – Shows user engagement depth. A ratio above 20% is considered strong.</li>
<li>EBITDA – Reflects core operational profitability and financial health. High EBITDA margins show sustainable growth and efficiency.</li>
</ol>
In 2024, video game M&amp;A activity reached $27.3 billion, underscoring the sector's immense growth and investment appeal. C-suite executives would be wise to consider these metrics when searching for their next target. 
<a href="https://www.benzinga.com/markets/asset-sales/25/05/45702349/deal-dispatch-beauty-brand-behavioral-health-firms-hit-auction-block">For last week&#8217;s edition of Deal Dispatch, click here</a>.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45816311/conagra-sells-seafood-brands-for-55m-as-it-sharpens-focus-on-core-business">Conagra Sells Seafood Brands For $55M As It Sharpens Focus On Core Business</a></li>
</ul>
Image created using a photo from Shutterstock.

Asset Sales

GDEV

GRDN

HOOD

KEYS

MLTX

POST

ROSE

SNOW

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

Morgan Stanley analyst Judah Frommer maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Equal-Weight and raises the price target from $102 to $129.

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $129

UBS analyst David Dai maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Neutral and raises the price target from $88 to $129.

UBS Maintains Neutral on Blueprint Medicines, Raises Price Target to $129

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Emily Bodnar upgraded the rating for AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Neutral to Buy and raised the price target from $22 to $38. AnaptysBio shares closed at $23.52 on Tuesday. <a href="https://www.benzinga.com/quote/ANAB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst David Anderson upgraded Cactus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) from Equal-Weight to Overweight and raised the price target from $51 to $54. Cactus shares closed at $44.11 on Tuesday. <a href="https://www.benzinga.com/quote/WHD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Cenk Orcan upgraded the rating for Embraer S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) from Hold to Buy and raises the price target from $45 to $57. Embraer shares closed at $45.99 on Tuesday. <a href="https://www.benzinga.com/quote/ERJ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst David Lebowitz upgraded Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sell to Neutral and raised the price target from $83 to $129. Blueprint Medicines shares closed at $127.60 on Tuesday. <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Karl Keirstead upgraded Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Buy and raised the price target from $210 to $265. Snowflake shares closed at $209.18 on Tuesday. <a href="https://www.benzinga.com/quote/snow/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SNOW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SNOW/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-1024x599.png" alt="" class="wp-image-938280" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

Upgrades

ANAB

Embraer-Empresa Brasileira De Aeronautica

This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Citigroup analyst David Lebowitz upgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sell to Neutral and raises the price target from $83 to $129.

Citigroup Upgrades Blueprint Medicines to Neutral, Raises Price Target to $129

JMP Securities analyst Reni Benjamin downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Market Outperform to Market Perform.

JMP Securities Downgrades Blueprint Medicines to Market Perform

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wolfe Research analyst Andy Chen downgraded the rating for Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Outperform to Peer Perform. Blueprint Medicines shares closed at $127.79 on Monday. <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Chris LaFemina downgraded Rio Tinto Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) from Buy to Hold. Rio Tinto shares closed at $59.58 on Monday. <a href="https://www.benzinga.com/quote/RIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Cory Carpenter downgraded the rating for Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) from Neutral to Underweight and maintained the price target of $5. Bumble shares closed at $5.74 on Monday. <a href="https://www.benzinga.com/quote/BMBL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Simon Coles downgraded ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) from Overweight to Equal-Weight. ASML shares closed at $746.53 on Monday. <a href="https://www.benzinga.com/quote/ASML/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Jackie Przybylowski downgraded the rating for MAC Copper Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTAL#NYSE">MTAL</a>) from Outperform to Market Perform but raised the price target from $11 to $12.25. MAC Copper shares closed at $12.24 on Monday. <a href="https://www.benzinga.com/quote/MTAL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ASML stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31-1024x588.png" alt="" class="wp-image-936720" style="width:666px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

ASML

BMBL

MTAL

This ASML Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>RBC Capital analyst Brad Erickson initiated coverage on Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Sector Perform rating and announced a price target of $125. Reddit shares closed at $112.11 on Monday. <a href="https://www.benzinga.com/quote/rddt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Jason Haas initiated coverage on ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) with an Equal-Weight rating and announced a price target of $56. ASGN shares closed at $51.72 on Monday. <a href="https://www.benzinga.com/quote/ASGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Matthew Vanvliet initiated coverage on Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with an Overweight rating and announced a price target of $325. Salesforce shares closed at $261.62 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Matthew Vanvliet initiated coverage on Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with an Overweight rating and announced a price target of $125. Agilysys shares closed at $108.20 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Alexander Pearce initiated coverage on Uranium Energy Corp.  (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UEC#AMEX">UEC</a>) with an Outperform rating and announced a price target of $7.75. Uranium Energy shares closed at $5.69 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying RDDT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30-1024x566.png" alt="" class="wp-image-936677" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30.png 1140w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

AGYS

ASGN

PINS

RDDT

This Salesforce Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Stephens &amp; Co. analyst Sudan Loganathan downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Overweight to Equal-Weight and lowers the price target from $150 to $135.

Stephens & Co. Downgrades Blueprint Medicines to Equal-Weight, Lowers Price Target to $135

Wolfe Research analyst Andy Chen downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Outperform to Peer Perform.

Wolfe Research Downgrades Blueprint Medicines to Peer Perform

Scotiabank analyst Louise Chen downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sector Outperform to Sector Perform and announces $135 price target.

Scotiabank Downgrades Blueprint Medicines to Sector Perform, Announces $135 Price Target

JP Morgan analyst Brian Cheng downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Overweight to Neutral and lowers the price target from $130 to $129.

JP Morgan Downgrades Blueprint Medicines to Neutral, Lowers Price Target to $129

U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Monday.
Shares of Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) rose sharply during Monday's session after the company <a href="https://www.benzinga.com/news/health-care/25/06/45720783/kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data">released ORIGIN Phase 3 trial data.</a>
Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p&lt;0.0001) at week 36.
Vera Therapeutics shares jumped 56.6% to $29.67 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) surged 44.8% to $9.89 after the company announced a 250MW AI data center lease with CoreWeave.</li>
<li>Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) climbed 33.3% to $39.53 after the company announced clinical data for its Phase 1 Healthy volunteer study of KT-621.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) gained 26.2% to $127.93 after the company announced that Sanofi will acquire them for $9.5 billion.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) gained 23.2% to $7.18 after Trump said he would double their tariffs to 50%.</li>
<li>Century Aluminum Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) rose 22% to $18.89 after Trump said he would double their tariffs to 50%.</li>
<li>Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) gained 18.2% to $17.64 after the company announced it began shipping its newly FDA-approved Yutrepia. Additionally, Needham raised its price target on the stock from $25 to $32.</li>
<li>REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) jumped 16.4% to $10.30.</li>
<li>Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) gained 14.1% to $62.95 after the company introduced its fuses program for precision-based medicine and xM for advanced cancer treatment response monitoring.</li>
<li>First Majestic Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) rose 10.6% to $6.83.</li>
<li>Steel Dynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) surged 10.5% to $135.93. Shares of steel and aluminum stocks traded higher after Trump said he would double their tariffs to 50%.</li>
<li>Hecla Mining Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HL#NYSE">HL</a>) gained 10.4% to $5.67.</li>
<li>Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) gained 10% to $120.20. BMO Capital analyst Katja Jancic upgraded Nucor from Market Perform to Outperform and raised the price target from $140 to $145.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 6.2% to $2.8250. ImmunityBio received FDA expanded access authorization for the treatment of Lymphopenia with ANKTIVA in patients with solid tumors</li>
<li>Eldorado Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGO#NYSE">EGO</a>) rose 6.1% to $21.32.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719355/top-3-utilities-stocks-that-may-crash-in-june">Top 3 Utilities Stocks That May Crash In June</a> </li>
</ul>
Photo via Shutterstock

CENX

IBRX

LQDA

RGNX

STLD

VERA

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Truist Securities raised Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $89 to $100. Truist Securities analyst Scot Ciccarelli maintained a Buy rating. Dollar Tree shares closed at $90.26 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">view this stock</a>.</li>
<li>Keybanc slashed the price target for UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from $450 to $400. Keybanc analyst Matthew Gillmor maintained an Overweight rating. UnitedHealth shares closed at $301.91 on Friday. <a href="https://www.benzinga.com/quote/UNH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) price target from $74 to $79. Raymond James analyst John Davis maintained an Outperform rating. Block shares closed at $61.75 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/xyz/analyst-ratings">view this stock</a>.</li>
<li>Wedbush increased the price target for Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from $128 to $129. Wedbush analyst David Nierengarten downgraded the stock from Outperform to Neutral. Blueprint Medicines shares closed at $101.35 on Friday. <a href="https://www.benzinga.com/quote/bpmc/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho increased the price target for SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from $15 to $18. Mizuho analyst Maheep Mandloi maintained a Neutral rating. SolarEdge Technologies shares closed at $17.86 on Friday. <a href="https://www.benzinga.com/quote/sedg/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS raised SPX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) price target from $160 to $182. UBS analyst Damian Karas upgraded the stock from Neutral to Buy. SPX Technologies shares settled at $152.09 on Friday. <a href="https://www.benzinga.com/quote/spxc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased EOG Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) price target from $132 to $135. Morgan Stanley analyst Devin McDermott maintained an Equal-Weight rating. EOG Resources shares closed at $108.57 on Friday. <a href="https://www.benzinga.com/quote/eog/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised Rollins, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) price target from $55 to $65. Jefferies analyst Stephanie Moore upgraded the stock from Hold to Buy. Rollins shares closed at $57.24 on Friday.  <a href="https://www.benzinga.com/quote/rol/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities increased the price target for The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from $185 to $260. B of A Securities analyst Ronald Epstein upgraded the stock from Neutral to Buy. Boeing shares settled at $207.29 on Friday. <a href="https://www.benzinga.com/quote/ba/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) price target from $45 to $65. Goldman Sachs analyst Jordan Alliger upgraded the stock from Neutral to Buy. Knight-Swift Transportation shares closed at $44.32 on Friday. <a href="https://www.benzinga.com/quote/knx/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying BA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-1024x579.png" alt="" class="wp-image-935238" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

DLTR

SEDG

SPXC

Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday

Press Releases

BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders

Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders

Legal

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, STR, BPMC, STRM on Behalf of Shareholders

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SAGE, SOL on Behalf of Shareholders

Comments

Blueprint Medicines

Actualités

Dernières nouvelles pour Blueprint Medicines (NASDAQ:BPMC) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL